- Home
- JAZZ vs MTG Comparison
JAZZ vs MTG Comparison
Compare JAZZ & MTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JAZZ | MTG |
|---|---|---|
| Founded | 2003 | 1957 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 5.9B |
| IPO Year | 2007 | 2008 |
Fundamental Metrics
Financial Performance| Metric | JAZZ | MTG |
|---|---|---|
| Price | $181.88 | $26.00 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 4 |
| Target Price | ★ $215.92 | $28.00 |
| AVG Volume (30 Days) | 966.4K | ★ 1.7M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 2.33% |
| EPS Growth | N/A | ★ 8.65 |
| EPS | N/A | ★ 3.14 |
| Revenue | ★ $1,618,693,000.00 | $1,213,636,000.00 |
| Revenue This Year | $6.17 | $3.24 |
| Revenue Next Year | $7.66 | $1.52 |
| P/E Ratio | ★ N/A | $8.21 |
| Revenue Growth | N/A | ★ 0.49 |
| 52 Week Low | $95.49 | $21.94 |
| 52 Week High | $198.00 | $29.97 |
Technical Indicators
Market Signals| Indicator | JAZZ | MTG |
|---|---|---|
| Relative Strength Index (RSI) | 55.28 | 42.02 |
| Support Level | $176.67 | $25.53 |
| Resistance Level | $198.00 | $27.77 |
| Average True Range (ATR) | 4.99 | 0.58 |
| MACD | -0.97 | -0.04 |
| Stochastic Oscillator | 42.49 | 27.76 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About MTG MGIC Investment Corporation
MGIC Investment Corp provides private mortgage insurance, other mortgage credit risk management solutions, and ancillary services. The insurance premiums that these customers pay for the protection accounts for close to majority of the company's total revenue. Investment income accounts for the remaining revenue. The company sells its insurance products in all states of the United States and in Puerto Rico. Its greatest exposure is in California, Florida, Texas, Pennsylvania, Ohio, Illinois, Virginia, North Carolina, Georgia and New York.